Reid Merryman, MD

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Reid Merryman, MD sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 2 currently recruiting early-phase tilt upper quartile by trial count

Reid Merryman, MD: 3 sponsored US clinical trials, 2 recruiting.

Reid Merryman, MD sponsors 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Follicular Lymphoma, with 3 trials.

Upper-quartile sponsor footprint

Reid Merryman, MD sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

3 total, page 1 of 1

RECRUITING Phase 2

Epco, Zanu, Ritux for R/R FL or MZL

NCT06563596
RECRUITING Phase 2

Epcoritamab and Rituximab for First-line Follicular Lymphoma

NCT05783609
ACTIVE NOT RECRUITING Phase 2

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

NCT05783596

Phase Distribution

PhaseTrial count
Phase 2 3

Therapeutic Areas

Follicular Lymphoma 3
Marginal Zone Lymphoma 2
Relapsed Lymphoma 1
Refractory Lymphoma 1
Low Grade Non-Hodgkin's Lymphoma, Adult 1
Indolent Non-Hodgkin Lymphoma 1
Non-Hodgkin Lymphoma 1
Lymphoma 1

What is open in the Reid Merryman, MD pipeline

2 recruiting of 3 indexed (67% open).

Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).

Top condition: Follicular Lymphoma (3 trials), 7 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Reid Merryman, MD: open-pipeline peers nationwide

Peers matched on 3 registered trials and 67% open enrollment, not the therapeutic-area sidebar.

Reid Merryman, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 234567 0%20%40%60%80% Total trials Recruiting share Reid Merryman, MD10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAbbisko Therapeutics CoABL BioAccelerated Cure Project for Multiple SclerosisAdvanced Reconstructive Surgery Alliance
Reid Merryman, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Reid Merryman, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 67% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Reid Merryman, MD page

3 registered trials is a research-attention snapshot, not an endorsement of Reid Merryman, MD or any single study.

  • 2 of Reid Merryman, MD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Follicular Lymphoma is the condition Reid Merryman, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Follicular Lymphoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Reid Merryman, MD pipeline card: 3 registered trials from official public datasets.Report a data error.